119 results
Page 3 of 6
8-K
EX-2.1
350zscllfx0ug8026b
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-10.1
limw0amm5no7
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
D
2pu52p808xs
23 Aug 21
$10.75M in options / securities to be acquired, sold $10.75M, 14 investors
4:15pm
424B5
5r43yxzrv6nn6wjkh
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
vmvb37r hooadj
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
njq6z2r
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
re71jff7 sq4fvi20m9p
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
fyrhu9 i3dz
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K/A
EX-99.1
jd1ipzdbz
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K
EX-10.3
uz5hzpvscc 9xl
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.1
zxzdachni1wtjft1qx
1 Feb 21
Departure of Directors or Certain Officers
6:55am
D
s9x9lges8lu
21 Jan 21
$8M in equity / options / securities to be acquired, sold $8M, 1 investor
4:15pm
8-K
EX-10.1
8djfivg62kqm
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.2
vec gg64b57k
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
D
9bgi8uty
4 Jan 21
Indefinite amount in equity, sold $3.2M, 15 investors
12:00am
8-K
EX-2.1
heg1lc6j
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-10.1
2he9fgol8
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am